{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:27:17Z","timestamp":1793834837853,"version":"4.6.1"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Neurogenic detrusor overactivity (NDO) is a complication of multiple sclerosis, spinal cord injury (SCI), stroke, head injury, and other conditions characterized by damage to the upper motor neuronal system. NDO often leads to high bladder pressure that may cause upper urinary tract damage and urinary incontinence (UI). Prior to the use of onabotulinumtoxinA, oral anticholinergics and surgical augmentation cystoplasty were the treatment options. Overactive bladder (OAB) is non-neurogenic and affects a much larger population than NDO. Both NDO and OAB negatively impact patients\u2019 quality of life (QOL) and confer high health care utilization burdens. Early positive results from pioneering investigators who injected onabotulinumtoxinA into the detrusor of patients with SCI caught the interest of Allergan, which then initiated collaborative clinical trials that resulted in FDA approval of onabotulinumtoxinA 200U in 2011 for NDO and 100U in 2013 for patients with OAB who inadequately respond to or are intolerant of an anticholinergic. These randomized, double-blind, placebo-controlled trials for NDO showed significant improvements in UI episodes, urodynamic parameters, and QOL; the most frequent adverse events were urinary tract infection (UTI) and urinary retention. Similarly, randomized, double-blind, placebo-controlled trials of onabotulinumtoxinA 100U for OAB found significant improvements in UI episodes, treatment benefit, and QOL; UTI and dysuria were the most common adverse events. Long-term studies in NDO and OAB showed sustained effectiveness and safety with repeat injections of onabotulinumtoxinA, the use of which has profoundly improved the QOL of patients failing anticholinergic therapy and has expanded the utilization of onabotulinumtoxinA into smooth muscle.<\/jats:p>","DOI":"10.1097\/md.0000000000032377","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:00:22Z","timestamp":1690484422000},"page":"e32377","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Victor","family":"Nitti","sequence":"first","affiliation":[{"name":"Division of Female Pelvic Medicine and Reconstructive Surgery, Departments of Urology and Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag-Molkenteller","sequence":"additional","affiliation":[{"name":"Urovant Sciences, Inc., Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kennelly","sequence":"additional","affiliation":[{"name":"Urology, Urogynecology, Female Pelvic Medicine and Reconstructive Surgery, Atrium Health, Charlotte, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chancellor","sequence":"additional","affiliation":[{"name":"Urology, Beaumont Hospital, Royal Oak, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schurch","sequence":"additional","affiliation":[{"name":"Neurourology Unit Department of Neurosciences, Centre Hospitalier Universitaire Vaudois, Universit\u00e9 de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240803","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000353274","article-title":"Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder.","volume":"41","author":"Ruffion","year":"2013","journal-title":"Neuroepidemiology"},{"key":"R2-20240803","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ucl.2010.06.005","article-title":"Spinal cord\/brain injury and the neurogenic bladder.","volume":"37","author":"Jeong","year":"2010","journal-title":"Urol Clin North Am"},{"issue":"10 Suppl","key":"R3-20240803","first-page":"s191","article-title":"The epidemiology and pathophysiology of neurogenic bladder.","volume":"19","author":"Ginsberg","year":"2013","journal-title":"Am J Manag Care"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database.","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines.","volume":"13","author":"de S\u00e8ze","year":"2007","journal-title":"Mult Scler"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/nau.23828","article-title":"Prevalence of lower urinary tract symptoms and overactive bladder in men and women over 18 years old: the Colombian overactive bladder and lower urinary tract symptoms (COBaLT) study.","volume":"38","author":"Plata","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study.","volume":"11","author":"Chuang","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"e11554","DOI":"10.1097\/MD.0000000000011554","article-title":"Epidemiology of lower urinary tract symptoms in a cross-sectional, population-based study: the status in China.","volume":"97","author":"Wang","year":"2018","journal-title":"Med Baltimore"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/nau.22295","article-title":"The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial\/ethnic group and age: results from OAB-POLL.","volume":"32","author":"Coyne","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States.","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2377-14-74","article-title":"Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity.","volume":"14","author":"Tang","year":"2014","journal-title":"BMC Neurol"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-11-13","article-title":"Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review.","volume":"11","author":"Tapia","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bju.12505","article-title":"Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.","volume":"113","author":"Tang","year":"2014","journal-title":"BJU Int"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS.","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"R18-20240803","first-page":"406","article-title":"Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics.","volume":"22","author":"Yehoshua","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"R19-20240803","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","article-title":"Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review.","volume":"75","author":"Bartoli","year":"2010","journal-title":"Urology"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12894-015-0009-6","article-title":"Correlation between psychological stress levels and the severity of overactive bladder symptoms.","volume":"15","author":"Lai","year":"2015","journal-title":"BMC Urol"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1464-410X.2010.10013.x","article-title":"The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.","volume":"108","author":"Coyne","year":"2011","journal-title":"BJU Int"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urology.2009.06.096","article-title":"Economic costs of overactive bladder in the United States.","volume":"75","author":"Ganz","year":"2010","journal-title":"Urology"},{"key":"R23-20240803","first-page":"130","article-title":"Economic burden of urgency urinary incontinence in the United States: a systematic review.","volume":"20","author":"Coyne","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"R25-20240803","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4111\/icu.2016.57.5.316","article-title":"Augmentation cystoplasty in neurogenic bladder.","volume":"57","author":"\u00c7etinel","year":"2016","journal-title":"Investig Clin Urol"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.sc.3100505","article-title":"The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results.","volume":"36","author":"Wiart","year":"1998","journal-title":"Spinal Cord"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<513::AID-NAU7>3.0.CO;2-G","article-title":"Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions.","volume":"17","author":"de S\u00e8ze","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/10790268.2003.11753706","article-title":"Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial.","volume":"26","author":"Kim","year":"2003","journal-title":"J Spinal Cord Med"},{"key":"R29-20240803","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2005.04.012","article-title":"Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.","volume":"48","author":"Silva","year":"2005","journal-title":"Eur Urol"},{"key":"R30-20240803","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.juro.2006.03.087","article-title":"Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study.","volume":"176","author":"Kuo","year":"2006","journal-title":"J Urol"},{"key":"R31-20240803","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.sc.3101584","article-title":"Intravesical therapy options for neurogenic detrusor overactivity.","volume":"42","author":"Reitz","year":"2004","journal-title":"Spinal Cord"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bju.13138","article-title":"Capsaicin, resiniferatoxin and botulinum toxin-A - a trip down memory lane.","volume":"115","author":"Dasgupta","year":"2015","journal-title":"BJU Int"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sc.1991.11","article-title":"Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.","volume":"29","author":"Madersbacher","year":"1991","journal-title":"Spinal Cord"},{"key":"R36-20240803","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1532-5415.2011.03491.x","article-title":"Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study.","volume":"59","author":"Fox","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"R37-20240803","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"R38-20240803","doi-asserted-by":"crossref","first-page":"e026391","DOI":"10.1136\/bmjopen-2018-026391","article-title":"Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.","volume":"9","author":"Szabo","year":"2019","journal-title":"BMJ Open"},{"key":"R39-20240803","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A.","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med"},{"key":"R41-20240803","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients.","volume":"139","author":"Dykstra","year":"1988","journal-title":"J Urol"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(05)64861-1","article-title":"Botulinum toxin for palmar hyperhidrosis.","volume":"349","author":"Naumann","year":"1997","journal-title":"Lancet"},{"issue":"3 Pt 1","key":"R44-20240803","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"key":"R45-20240803","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"R46-20240803","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1310\/1640-XEPP-Y33E-TMK8","article-title":"Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia.","volume":"8","author":"Kennelly","year":"2003","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"R47-20240803","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0361-9230(03)00114-X","article-title":"Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions.","volume":"61","author":"Smith","year":"2003","journal-title":"Brain Res Bull"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/01.ju.0000049202.56189.54","article-title":"Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract.","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"R49-20240803","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.","volume":"176","author":"Schmid","year":"2006","journal-title":"J Urol"},{"key":"R50-20240803","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"R51-20240803","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R52-20240803","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur Urol"},{"key":"R53-20240803","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00192-011-1655-1","article-title":"Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.","volume":"23","author":"Brubaker","year":"2012","journal-title":"Int Urogynecol J"},{"key":"R55-20240803","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"R56-20240803","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"R57-20240803","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of concomitant anticholinergic use or neurologic etiology.","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv Ther"},{"key":"R58-20240803","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/nau.22376","article-title":"OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.","volume":"32","author":"Rovner","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"R59-20240803","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1212\/WNL.0b013e3182a2ca4d","article-title":"OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.","volume":"81","author":"Chancellor","year":"2013","journal-title":"Neurology"},{"key":"R60-20240803","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/nau.22293","article-title":"Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.","volume":"32","author":"Sussman","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"R61-20240803","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/nau.22757","article-title":"Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity.","volume":"35","author":"Chartier-Kastler","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"R63-20240803","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/nau.22934","article-title":"Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study.","volume":"36","author":"Kennelly","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"R64-20240803","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.juro.2016.04.046","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment.","volume":"196","author":"Rovner","year":"2016","journal-title":"J Urol"},{"key":"R65-20240803","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/bju.13795","article-title":"Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity.","volume":"119","author":"Denys","year":"2017","journal-title":"BJU Int"},{"key":"R66-20240803","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1212\/WNL.0000000000005991","article-title":"Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.","volume":"91","author":"Tullman","year":"2018","journal-title":"Neurology"},{"key":"R67-20240803","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence.","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R68-20240803","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"R69-20240803","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"R70-20240803","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.","volume":"68","author":"Sievert","year":"2014","journal-title":"Int J Clin Pract"},{"key":"R71-20240803","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/cer-2018-0079","article-title":"Cost-effectiveness of overactive bladder treatments: from the US payer perspective.","volume":"8","author":"Murray","year":"2019","journal-title":"J Comp Eff Res"},{"key":"R72-20240803","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00192-018-3653-z","article-title":"A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder.","volume":"29","author":"Shepherd","year":"2018","journal-title":"Int Urogynecol J"},{"key":"R73-20240803","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/iju.12912","article-title":"Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: a pooled analysis of two randomized controlled trials.","volume":"22","author":"Everaert","year":"2015","journal-title":"Int J Urol"},{"key":"R74-20240803","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5 year study.","volume":"196","author":"Nitti","year":"2016","journal-title":"J Urol"},{"key":"R75-20240803","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.juro.2017.05.068","article-title":"Long-term treatment with onabotulinumtoxinA results in consistent, durable improvements in health related quality of life in patients with overactive bladder.","volume":"198","author":"Ginsberg","year":"2017","journal-title":"J Urol"},{"key":"R76-20240803","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","article-title":"The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin na\u00efve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial.","volume":"198","author":"Herschorn","year":"2017","journal-title":"J Urol"},{"key":"R77-20240803","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","article-title":"Early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial.","volume":"27","author":"McCammon","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"R78-20240803","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0149-2918(00)83049-0","article-title":"Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.","volume":"22","author":"Brashear","year":"2000","journal-title":"Clin Ther"},{"key":"R79-20240803","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"R80-20240803","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1524-4725.2012.02582.x","article-title":"OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines.","volume":"38","author":"Glogau","year":"2012","journal-title":"Dermatol Surg"},{"key":"R81-20240803","first-page":"964","article-title":"Motor nerve sprouting in human orbicularis muscle after botulinum A injection.","volume":"31","author":"Holds","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R82-20240803","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2004.07.011","article-title":"Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder.","volume":"46","author":"Haferkamp","year":"2004","journal-title":"Eur Urol"},{"key":"R83-20240803","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.01.009","article-title":"Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.","volume":"56","author":"Lowe","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R84-20240803","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/archderm.139.6.731","article-title":"Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.","volume":"139","author":"Naumann","year":"2003","journal-title":"Arch Dermatol"},{"key":"R85-20240803","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.neuint.2004.06.001","article-title":"Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury.","volume":"45","author":"Khera","year":"2004","journal-title":"Neurochem Int"},{"issue":"4 Pt 1","key":"R86-20240803","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","article-title":"Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats.","volume":"172","author":"Chuang","year":"2004","journal-title":"J Urol"},{"key":"R87-20240803","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J Urol"},{"key":"R88-20240803","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/membranes4030525","article-title":"Trafficking of thermoTRP channels.","volume":"4","author":"Ferrandiz-Huertas","year":"2014","journal-title":"Membranes (Basel)"},{"key":"R89-20240803","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11934-016-0585-3","article-title":"Indications for augmentation cystoplasty in the era of onabotulinumtoxinA.","volume":"17","author":"Shreck","year":"2016","journal-title":"Curr Urol Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:12Z","timestamp":1722736572000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":82,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032377","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}